Novartis' Rhapsido tackles 2 most common forms of chronic hives with swift FDA expansion

Novartis' oral BTK inhibitor Rhapsido (remibrutinib) received FDA approval as the first treatment for symptomatic dermographism (SD) uncontrolled by H1 antihistamines, expanding its earlier chronic spontaneous urticaria (CSU) indication. This makes Rhapsido the only chronic hives drug approved for both SD and CSU, supported by late-stage trial data showing superior symptom control compared to placebo.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 7 Oct 2026 and 10 Oct 2026.